This is the best part of the RNS
#avct ❤️🥇 incredible:
‘Tumor tissue studies from this experiment demonstrate that tumors treated with AVA6103 have increased FAP expression over time via immunohistochemistry, with recruitment of FAP+ fibroblasts over the course of treatment
1/2
My thoughts:
*CC was excellent again. Discussing complexity with clarity & terminology that was absorbing for all.
*confidence was high. 6103 readout being a close match to pre-clinical was the standout moment of the presentation for me. They must be seeing efficacy
1/4 #avct
*6000 feels ‘side of desk’ with 6103 performing (maybe rightly so).
Potentially BP feel the same.
*this time next year Rodney 👏🏻
Happy investor. SP is an opportunity, but must raise significantly through next year or unanswered commercial Q’s will be brought to a head
4/4 #avct
Slept on it & still disappointed. #avct
Ben captures my thoughts well. A good post.
fear for 6k is that nobody wants to deal at any decent value, as a next gen dox would wipe the floor (capping +pre|C +linker +dox) 🤔
Feels like an all or nothing crescendo on 6103 efficacy
3
12
2,004
If they thought the SP would rise post-announcement in the hope to raise with lower dilution; they would have done so closer to the announcement.
Personally I suspect #avct were not happy with the best offer, given efficacy is still ‘a risk for BP’ due to not yet being confirmed
2
1
2,110
If I’m reading right, cash burn was £5m per month July & August.
Likely due to trial setup inc manufacturing + bond.
Assuming that continues, cash sits at circa £7m hence the raise.
If they want to raise into tail of H1, I suspect this will be hefty . Needs to inc bond #avct
1/3
2
3
2,062
I see this as another example of #avct SH’s being victim of the co’s success.
Clearly BoD see more value in further data validation given the positive PK&PD of 6103.
I don’t disagree.
This is biotech & I trust BoD to extract max value long term.
Only shame is the Likely £price
1
4
1,272
During 6k trials, partial responses were RNS’d as they occurred.
This almost certainly won’t be the case for 6103.
Imo, we get the 6103 efficacy data & Partner announcement on the same day across 2 RNS towards the tail end of H1.
6k & 6207 partners…. Who knows 🤷♂️
1/2
#avct
